Cargando…

Predicting response to HER2 kinase inhibition

Detalles Bibliográficos
Autor principal:	Settleman, Jeff
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2014
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4359239/ https://www.ncbi.nlm.nih.gov/pubmed/25655645

Ejemplares similares

HER kinase inhibition in patients with HER2- and HER3-mutant cancers
por: Hyman, David M., et al.
Publicado: (2018)

Optimizing the treatment of BRAF mutant melanoma
por: Settleman, Jeff
Publicado: (2014)

Rho-kinase regulates tissue morphogenesis via non-muscle myosin and LIM-kinase during Drosophila development
por: Verdier, Valerie, et al.
Publicado: (2006)

Discovering Tumor Suppressor Genes Through Genome-Wide Copy Number Analysis
por: Rothenberg, S. Michael, et al.
Publicado: (2010)

Integrating complex genomic datasets and tumour cell sensitivity profiles to address a 'simple' question: which patients should get this drug?
por: Benes, Cyril, et al.
Publicado: (2009)

HER2 therapy. Small molecule HER-2 tyrosine kinase inhibitors
por: Spector, Neil, et al.
Publicado: (2007)

HER2-positive feline mammary carcinoma
por: Marques, Cláudia, et al.
Publicado: (2016)

Bevacizumab in HER2-negative inflammatory breast cancer
por: Bertucci, François, et al.
Publicado: (2016)

Intrinsic molecular subtypes of HER2+ breast cancer
por: Prat, Aleix, et al.
Publicado: (2017)

Lapatinib, a Dual EGFR and HER2 Tyrosine Kinase Inhibitor, Downregulates Thymidylate Synthase by Inhibiting the Nuclear Translocation of EGFR and HER2
por: Kim, Hwang-Phill, et al.
Publicado: (2009)

Current status of PI3K-mTOR inhibition in hormone-receptor positive, HER2-negative breast cancer
por: Sobhani, Navid, et al.
Publicado: (2018)

Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition
por: Rexer, Brent N., et al.
Publicado: (2011)

Hyperproliferation of the Intestinal Epithelium: HER2-Day, Gone Tomorrow
por: Dekaney, Christopher M.
Publicado: (2021)

The uncharted role of HER2 mutant alleles in breast cancer
por: Kalra, Rashi, et al.
Publicado: (2023)

Pyrotinib as a therapeutic for HER2-positive breast cancer
por: Kioutchoukova, Ivelina, et al.
Publicado: (2023)

Comparative docking analysis of tyrosine kinase inhibitors with HER2 and HER4 receptors
por: Sonar, Priyanka, et al.
Publicado: (2022)

Screening for functional kinases in metastatic prostate cancer: a glimmer of hope for kinase inhibition
por: Ornstein, Moshe C., et al.
Publicado: (2016)

Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancer
por: Punturi, Nindo B., et al.
Publicado: (2021)

HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+ breast cancer
por: Green, Andrew R., et al.
Publicado: (2014)

Escape from HER family tyrosine kinase inhibitor therapy by the kinase inactive HER3
por: Sergina, Natalia V., et al.
Publicado: (2007)

PTK (protein tyrosine kinase)-6 and HER2 and 4, but not HER1 and 3 predict long-term survival in breast carcinomas
por: Aubele, M, et al.
Publicado: (2007)

Circulating fatty acid synthase: an exploratory biomarker to predict efficacy of the dual HER1/HER2 tyrosine kinase inhibitor lapatinib
por: Oliveras-Ferraros, Cristina, et al.
Publicado: (2011)

Selective Inhibition of Extracellular Signal-regulated Kinases 1 and 2: When Less Is More
por: Hao, Yuan, et al.
Publicado: (2022)

GM-CSF - an oncogenic driver of HER2+ breast leptomeningeal metastasis
por: Garg, Rachana, et al.
Publicado: (2022)

Phase I clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion
por: Hamilton, Erika, et al.
Publicado: (2012)

Biased activation of the receptor tyrosine kinase HER2
por: Catapano, Claudia, et al.
Publicado: (2023)

Response to HER2 Inhibition in a Patient With Brain Metastasis With EGFR TKI Acquired Resistance and an HER2 Amplification
por: Meedendorp, Arenda D., et al.
Publicado: (2018)

HER-3: hub for escape mechanisms
por: Capone, Emily, et al.
Publicado: (2015)

Bones Ejected from Her Body
Publicado: (1891)

Nursing Her Wrath to Keep It Warm
Publicado: (1862)

Determining the Factors Predicting the Response to Anti-HER2 Therapy in HER2-Positive Breast Cancer Patients
por: You, Ji Young, et al.
Publicado: (2023)

Predictive value of quantitative HER2, HER3 and p95HER2 levels in HER2-positive advanced breast cancer patients treated with lapatinib following progression on trastuzumab
por: Duchnowska, Renata, et al.
Publicado: (2017)

p16(INK4A)-deficiency predicts response to combined HER2 and CDK4/6 inhibition in HER2+ breast cancer brain metastases
por: Ni, Jing, et al.
Publicado: (2022)

Inhibition of the transcriptional kinase CDK7 overcomes therapeutic resistance in HER2-positive breast cancers
por: Sun, Bowen, et al.
Publicado: (2019)

Pregnancies in young women with diagnosis and treatment of HER2-positive breast cancer
por: Lambertini, Matteo, et al.
Publicado: (2019)

HER2 expression should be routinely evaluated in DCIS to avoid under or overtreatment!
por: Garg, Nidhi, et al.
Publicado: (2023)

HER-2-Positive Tumors: A Continuously Evolving Field in Cancer Research
por: Hofheinz, Ralf, et al.
Publicado: (2023)

Correction: phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion
por: Hamilton, Erika, et al.
Publicado: (2013)

Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitors
por: Conlon, Neil T., et al.
Publicado: (2021)

Drugs of Dependency: The Pregnant Woman and Her Infant
por: Oei, Julee, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_vfdhl0viibmaho1b5jdn8rvnjh